Related Experiment Video
Updated: Aug 8, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer
Ho-Young Lee1, Kyung-Hee Chun, Bingrong Liu
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. hlee@mdanderson.org
Abstract:
Insulin-like growth factors (IGFs) have mitogenic and antiapoptotic properties and have been implicated in the development of lung cancer. The effects of IGFs are modulated by insulin-like growth factor binding proteins (IGFBPs). This study explored the effects of IGFBP-3 on non-small cell lung cancer (NSCLC) cells after infection with an adenovirus constitutively expressing IGFBP-3 under the control of the cytomegalovirus promoter (Ad5CMV-BP3). We found that IGFs, especially IGF-I, stimulated the growth of NSCLC cells, and Ad5CMV-BP3 suppressed this IGF-I-induced NSCLC cell growth. We also found that the clonogenicity of H1299 cells in soft agar was markedly reduced by Ad5CMV-BP3. Furthermore, direct injection of Ad5CMV-BP3 into H1299 NSCLC xenografts s.c. established in athymic nude mice induced massive destruction of the tumors. Ad5CMV-BP3 did not induce detectable cytotoxicity on normal human bronchial epithelial cells, suggesting therapeutic efficacy of this virus. Ad5CMV-BP3 infection was accompanied by apoptotic cell death in vitro as detected by flow cytometry, DNA fragmentation analysis, and Western blot analysis on the expression of Bcl-2 and on the cleavage of poly(ADP-ribose) polymerase, a substrate of caspase 3. Immunofluorescence confocal microscopy was also used to show the apoptotic effect of Ad5CMV-BP3 in H1299 tumors established in nude mice. These findings indicated that IGFBP-3 was a potent inducer of apoptosis in NSCLC cells in vitro and in vivo. To delineate the underlying mechanism, we examined the effect of IGFBP-3 on Akt/protein kinase B and glycogen synthase kinase-3beta, downstream mediators of the phosphatidylinositol 3-kinase pathway, and on mitogen-activated protein kinase (MAPK), all three of which are activated by IGF-mediated signaling pathways and have important roles in cell survival. IGFBP-3 overexpression inhibited the phosphorylation of Akt and glycogen synthase kinase-3beta and the activity of MAPK. Furthermore, IGF-I rescued the NSCLC cells from serum depletion-induced apoptosis, and this rescue was blocked in Ad5CMV-BP-3-infected H1299 NSCLC cells. Transient transfection with activated Akt or constitutively active MAPK kinase-1, an upstream activator of MAPK, partially blocked IGFBP-3-induced apoptosis of NSCLC cells. These findings suggested that the growth-regulatory effect of IGFBP-3 on NSCLC cells was attributable in part to the inhibition of the IGF-induced survival pathway. These data demonstrate the importance of IGFBP-3 in the regulation of NSCLC cell proliferation, clonogenicity, and tumor growth, suggesting that IGFBP-3 is a target for the treatment of lung cancer and that Ad5CMV-BP3 is a potential therapeutic agent.
Insights
Insulin-like growth factor binding protein-3 (IGFBP-3) delivered via adenovirus (Ad5CMV-BP3) effectively suppresses non-small cell lung cancer (NSCLC) growth and induces apoptosis. This targeted therapy shows promise for lung cancer treatment with minimal toxicity to normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Insulin-like growth factors (IGFs) promote lung cancer cell growth and survival.
- IGF effects are regulated by insulin-like growth factor binding proteins (IGFBPs).
- IGFBP-3's role in non-small cell lung cancer (NSCLC) warrants further investigation.
Purpose of the Study:
- To investigate the therapeutic potential of IGFBP-3 delivered by adenovirus (Ad5CMV-BP3) in NSCLC.
- To elucidate the mechanisms by which IGFBP-3 affects NSCLC cell proliferation, apoptosis, and tumor growth.
Main Methods:
- Infection of NSCLC cells with Ad5CMV-BP3.
- Assessment of cell growth, clonogenicity, and apoptosis in vitro and in vivo.
- Analysis of signaling pathways including Akt/protein kinase B, GSK-3beta, and MAPK.
- Xenograft models in athymic nude mice.
Main Results:
- Ad5CMV-BP3 suppressed IGF-I-stimulated NSCLC cell growth and reduced clonogenicity.
- Direct injection of Ad5CMV-BP3 caused significant tumor destruction in vivo with no toxicity to normal bronchial cells.
- Ad5CMV-BP3 induced apoptosis in NSCLC cells via inhibition of IGF-mediated survival pathways (Akt, MAPK).
Conclusions:
- IGFBP-3 is a potent inducer of apoptosis in NSCLC cells.
- Ad5CMV-BP3 demonstrates therapeutic efficacy against NSCLC in vitro and in vivo.
- IGFBP-3 represents a promising therapeutic target for lung cancer treatment.
Related Concept Videos
Mitogens and the Cell Cycle
Regulation of Angiogenesis and Blood Supply

